News

The Stephenson Cancer Center is bringing a promising new investigational drug to Oklahoma patients faced with a potentially deadly form of skin cancer. The Stephenson Cancer Center is the first and only institution in Oklahoma to offer the investigational drug vemurafenib as part of an “expanded access” clinical trial. The clinical trial is enrolling patients in this state with a common form of metastatic melanoma, the deadliest form of skin cancer.

Read more >

An Oklahoma scientist studying the role of protein interaction in the formation of prostate cancer has been awarded a $1.5 million research grant by the National Cancer Institute to further his work for the next five years. Ralf Janknecht, PhD, the director of the Basic Cancer Biology Program at the Stephenson Cancer Center, was awarded the grant after a rigorous competitive review of his project.

Read more >